Comprehensive interrogation of the ADAR2 deaminase domain for engineering enhanced RNA editing activity and specificity

  1. Dhruva Katrekar
  2. Yichen Xiang
  3. Nathan Palmer
  4. Anushka Saha
  5. Dario Meluzzi
  6. Prashant Mali  Is a corresponding author
  1. University of California, San Diego, United States

Abstract

Adenosine deaminases acting on RNA (ADARs) can be repurposed to enable programmable RNA editing, however their enzymatic activity on adenosines flanked by a 5' guanosine is very low, thus limiting their utility as a transcriptome engineering toolset. To address this issue, we first performed a novel deep mutational scan of the ADAR2 deaminase domain, directly measuring the impact of every amino acid substitution across 261 residues, on RNA editing. This enabled us to create a domain wide mutagenesis map while also revealing a novel hyperactive variant with improved enzymatic activity at 5'-GAN-3' motifs. However, exogenous delivery of ADAR enzymes, especially hyperactive variants, leads to significant transcriptome wide off-targeting. To solve this problem, we engineered a split ADAR2 deaminase which resulted in 1000-fold more specific RNA editing as compared to full-length deaminase overexpression. We anticipate that this systematic engineering of the ADAR2 deaminase domain will enable broader utility of the ADAR toolset for RNA biotechnology and therapeutic applications.

Data availability

Sequencing data will be accessible via NCBI GEO under accession GSE158656. Source data has been made available with the submission.

The following data sets were generated
    1. Katrekar D
    (2022) ADAR Protein Engineering
    NCBI Gene Expression Omnibus, GSE158656.

Article and author information

Author details

  1. Dhruva Katrekar

    Bioengineering, University of California, San Diego, La Jolla, United States
    Competing interests
    Dhruva Katrekar, has filed a patent pertaining to the screening methodology, novel mutants and splitting of the ADAR2-DD (application number: 63/075,717). Is now an employee of Shape Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8028-3244
  2. Yichen Xiang

    Department of Bioengineering, University of California, San Diego, La Jolla, United States
    Competing interests
    No competing interests declared.
  3. Nathan Palmer

    Division of Biological Sciences, University of California, San Diego, La Jolla, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6347-9379
  4. Anushka Saha

    Department of Bioengineering, University of California, San Diego, La Jolla, United States
    Competing interests
    No competing interests declared.
  5. Dario Meluzzi

    Department of Bioengineering, University of California, San Diego, La Jolla, United States
    Competing interests
    No competing interests declared.
  6. Prashant Mali

    Department of Bioengineering, University of California, San Diego, La Jolla, United States
    For correspondence
    pmali@ucsd.edu
    Competing interests
    Prashant Mali, has filed a patent pertaining to the screening methodology, novel mutants and splitting of the ADAR2-DD (application number: 63/075,717). Is a scientific co-founder of Shape Therapeutics, Navega Therapeutics, Boundless Biosciences, and Engine Biosciences..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3383-1287

Funding

National Human Genome Research Institute (R01HG009285)

  • Prashant Mali

National Cancer Institute (R01CA222826)

  • Prashant Mali

National Institute of General Medical Sciences (R01GM123313)

  • Prashant Mali

U.S. Department of Defense (PR210085)

  • Prashant Mali

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2022, Katrekar et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,294
    views
  • 712
    downloads
  • 34
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Dhruva Katrekar
  2. Yichen Xiang
  3. Nathan Palmer
  4. Anushka Saha
  5. Dario Meluzzi
  6. Prashant Mali
(2022)
Comprehensive interrogation of the ADAR2 deaminase domain for engineering enhanced RNA editing activity and specificity
eLife 11:e75555.
https://doi.org/10.7554/eLife.75555

Share this article

https://doi.org/10.7554/eLife.75555

Further reading

    1. Biochemistry and Chemical Biology
    Jianheng Fox Liu, Ben R Hawley ... Samie R Jaffrey
    Tools and Resources

    N 6,2’-O-dimethyladenosine (m6Am) is a modified nucleotide located at the first transcribed position in mRNA and snRNA that is essential for diverse physiological processes. m6Am mapping methods assume each gene uses a single start nucleotide. However, gene transcription usually involves multiple start sites, generating numerous 5’ isoforms. Thus, gene-level annotations cannot capture the diversity of m6Am modification in the transcriptome. Here, we describe CROWN-seq, which simultaneously identifies transcription-start nucleotides and quantifies m6Am stoichiometry for each 5’ isoform that initiates with adenosine. Using CROWN-seq, we map the m6Am landscape in nine human cell lines. Our findings reveal that m6Am is nearly always a high stoichiometry modification, with only a small subset of cellular mRNAs showing lower m6Am stoichiometry. We find that m6Am is associated with increased transcript expression and provide evidence that m6Am may be linked to transcription initiation associated with specific promoter sequences and initiation mechanisms. These data suggest a potential new function for m6Am in influencing transcription.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Joar Esteban Pinto Torres, Mathieu Claes ... Yann G-J Sterckx
    Research Article

    African trypanosomes are the causative agents of neglected tropical diseases affecting both humans and livestock. Disease control is highly challenging due to an increasing number of drug treatment failures. African trypanosomes are extracellular, blood-borne parasites that mainly rely on glycolysis for their energy metabolism within the mammalian host. Trypanosomal glycolytic enzymes are therefore of interest for the development of trypanocidal drugs. Here, we report the serendipitous discovery of a camelid single-domain antibody (sdAb aka Nanobody) that selectively inhibits the enzymatic activity of trypanosomatid (but not host) pyruvate kinases through an allosteric mechanism. By combining enzyme kinetics, biophysics, structural biology, and transgenic parasite survival assays, we provide a proof-of-principle that the sdAb-mediated enzyme inhibition negatively impacts parasite fitness and growth.